Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INT 767

Next Previous
Drug Profile

INT 767

Alternative Names: Dual FXR/TGR5 agonists - Intercept Pharmaceuticals; FXR & TGR5 BA-derived backups - Intercept Pharmaceuticals; INT-767

Latest Information Update: 13 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intercept Pharmaceuticals
  • Class Anti-inflammatories; Antifibrotics; Bile acids and salts; Cholanes; Hepatoprotectants; Small molecules; Sulfates
  • Mechanism of Action Farnesoid X-activated receptor agonists; G protein-coupled receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic nephropathies; Hepatic fibrosis; Metabolic disorders; Non-alcoholic steatohepatitis

Most Recent Events

  • 05 Jun 2024 Interim pharmacodynamics data from a preclinical development in Metabolic disorders presented at the European Association for the Study of the Liver Congress 2024 (EASL Congress 2024)
  • 08 Nov 2023 Intercept Pharmaceuticals has been acquired by Alfasigma
  • 12 Nov 2021 Pharmacodynamics data from preclinical studies in Hepatic fibrosis presented at the 72nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top